Sorrento Therapeutics Inc. (SRNE) Social Stream



Sorrento Therapeutics Inc. (SRNE): $2.59

-0.18 (-6.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 404

in industry

Sorrento Therapeutics Inc (SRNE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Sorrento Therapeutics Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-12-28 3 $35 $19 $26.666 $2.32 1049.4%
2022-01-04 3 $35 $18 $26.333 $2.32 1035.04%
2022-02-18 2 $26 $18 $22 $2.32 848.28%
2022-03-25 2 $20 $18 $19 $2.32 718.97%

The Trend in the Analyst Price Target


Over the past 22 months, SRNE's average price target has gone down $5.

SRNE reports an average of 305.64% for its upside potential over the past 50 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-07-10 4 35 19 28.00 8.69 222.21%
2021-08-07 4 35 19 28.00 8.39 233.73%
2021-08-28 3 35 19 26.67 9.15 191.48%
2022-01-04 2 26 18 22.00 4.73 365.12%
2022-02-10 2 26 18 22.00 3.33 560.66%

SRNE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 2 0 0 0 0 2

The Trend in the Broker Recommendations


Over the past 30 weeks, SRNE's average broker recommendation rating improved by 1.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SRNE as an investment opportunity.

  • In the context of all US stocks, Sorrento Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 394.46% of them.
  • SRNE has a greater number of analysts covering the stock than 22.14% of stocks in the mid market cap category.
  • SRNE has a higher average analyst price target than 103.41% of stocks in the mid market cap category.
  • SRNE has a lower variance in analysts' estimates than -111.51% of stocks in the mid market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Sorrento Therapeutics Inc are SGMO, SANA, and RXRX.

Is SRNE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4527 seconds.